Search research articles
Contact Us
Filters
Showing results (31-40 of 36) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 36 results.
BMC Cancer
|
October 24, 2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
R Glynne-Jones, N Hava, V Goh, et al.
British Journal of Cancer
|
April 20, 2022
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
E Van Cutsem, I Danielewicz, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2020
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
E Van Cutsem, I Danielewicz, M P Saunders, et al.
British Journal of Cancer
|
May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
P G Corrie, W Qian, B Basu, et al.
ESMO Open
|
June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2016
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 36) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 36 results.
BMC Cancer
|
October 24, 2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
R Glynne-Jones, N Hava, V Goh, et al.
British Journal of Cancer
|
April 20, 2022
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
E Van Cutsem, I Danielewicz, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2020
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
E Van Cutsem, I Danielewicz, M P Saunders, et al.
British Journal of Cancer
|
May 1, 2020
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
P G Corrie, W Qian, B Basu, et al.
ESMO Open
|
June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2016
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, et al.
Page
of 4